<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327170</url>
  </required_header>
  <id_info>
    <org_study_id>SDMCCSC-FM</org_study_id>
    <nct_id>NCT01327170</nct_id>
  </id_info>
  <brief_title>Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy</brief_title>
  <official_title>Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate safety and therapeutic response to micropulse diode
      810nm laser treatment in patients with chronic central serous chorioretinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most of the cases of central serous chorioretinopathy (CSC) recur spontaneously within three
      months of disease. After 3 months without resolution of acute CSC or in chronic CSC,
      continuous wave laser photocoagulation or photodynamic therapy should be considered. Direct
      threshold continuous photocoagulation treatment can shorten the duration of the serous
      detachment, but it is not appropriate for juxtafoveal or subfoveal leakage point.Subvisible
      photocoagulation potentially localizes and decreases chorioretinal thermic burn. Subthreshold
      diode micropulse (SDM) laser using a 810nm diode laser may spare the damage to the neural
      retina by raising the temperature of the RPE to just below the protein-denaturation threshold
      so that the thermal wave that reaches the neural retina is insufficient to cause neither
      damage nor clinically visible end-point. This therapeutic laser modality offers the
      possibility to minimize the iatrogenic retinal lesion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Best corrected visual acuity measured by ETDRS chart at baseline, 1, 3, 6, 9 and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular subretinal fluid</measure>
    <time_frame>6 months</time_frame>
    <description>Central macular thickness measured by spectral-domain optical coherence tomography at baseline, 1, 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leakage at fluorescein angiogram</measure>
    <time_frame>6 months</time_frame>
    <description>Leakage at fluorescein angiogram evaluated at baseline, 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Subthreshold diode micropulse laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham group simulating the laser treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subthreshold diode micropulse laser</intervention_name>
    <arm_group_label>Subthreshold diode micropulse laser</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic active central serous chorioretinopathy lasting more than 6 months

          -  Leakage at fluorescein angiogram

        Exclusion Criteria:

          -  Opacities of the clear refractive media of the eye

          -  Any intraocular surgery within the 6 months prior to study entry

          -  Prior vitrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda P Magalhaes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>March 30, 2011</last_update_submitted>
  <last_update_submitted_qc>March 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fernanda Pedreira Magalhães</name_title>
    <organization>Federal University of São Paulo</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

